Published in Cancer Res on August 15, 2006
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (2011) 1.64
Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet (2012) 1.47
CASE-CONTROL SURVIVAL ANALYSIS WITH A GENERAL SEMIPARAMETRIC SHARED FRAILTY MODEL - A PSEUDO FULL LIKELIHOOD APPROACH. Ann Stat (2009) 1.43
Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet (2010) 1.39
Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer (2007) 1.38
Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat (2012) 1.30
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol (2008) 1.19
Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One (2012) 1.15
Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol (2008) 1.14
Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet (2011) 1.12
Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res (2007) 1.09
BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: explanation for the "BRCA paradox"? PLoS One (2012) 1.07
Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat (2010) 1.05
Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun (2015) 1.02
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer Inform (2008) 0.98
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol (2014) 0.94
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One (2013) 0.92
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases. Fam Cancer (2012) 0.91
Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve. Int J Endocrinol (2013) 0.90
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer (2013) 0.90
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer (2009) 0.89
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer (2015) 0.88
Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat (2014) 0.88
Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat (2011) 0.88
A frailty-model-based approach to estimating the age-dependent penetrance function of candidate genes using population-based case-control study designs: an application to data on the BRCA1 gene. Biometrics (2009) 0.88
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol (2011) 0.86
Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality". Mol Ther Nucleic Acids (2013) 0.85
Family history of cancer and risk of breast cancer in the Black Women's Health Study. Cancer Causes Control (2009) 0.85
Examination of ancestral informative markers and self-reported race with tumor characteristics of breast cancer among Black and White women. Breast Cancer Res Treat (2012) 0.84
The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat (2015) 0.83
Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. Front Genet (2012) 0.83
Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. World J Surg (2012) 0.83
BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families. BMC Med Genet (2013) 0.83
Updating and refining a study brochure for a cancer registry-based study of BRCA mutations among young African American breast cancer patients: lessons learned. J Community Genet (2010) 0.83
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran (2016) 0.83
A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer (2015) 0.82
Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer. J Clin Oncol (2016) 0.81
The effect of patient characteristics on second primary cancer risk in France. BMC Cancer (2014) 0.81
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Fam Cancer (2012) 0.81
A comparative study of disease genes and drug targets in the human protein interactome. BMC Bioinformatics (2015) 0.80
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer (2015) 0.80
An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer (2013) 0.79
African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer. J Genet Couns (2013) 0.78
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. PLoS One (2015) 0.78
BRCA sequencing and large rearrangement testing in young Black women with breast cancer. J Community Genet (2013) 0.77
Could triaging family history of cancer during palliative care enable earlier genetic counseling intervention? J Palliat Med (2013) 0.77
Missing genetic information in case-control family data with general semi-parametric shared frailty model. Lifetime Data Anal (2010) 0.76
The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. Breast Cancer Res Treat (2015) 0.76
A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer (2011) 0.75
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J (2015) 0.75
Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women. Patient Educ Couns (2016) 0.75
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget (2016) 0.75
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer (2016) 0.75
Classification of Cancer Primary Sites Using Machine Learning and Somatic Mutations. Biomed Res Int (2015) 0.75
Preventive care and evaluation of the adolescent with a breast mass. Semin Plast Surg (2013) 0.75
How reliable are BRCA1/2 mutation estimates? Cancer Res (2007) 0.75
Recruitment of a Population-Based Sample of Young Black Women with Breast Cancer through a State Cancer Registry. Breast J (2015) 0.75
Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features. Biomed Res Int (2017) 0.75
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. Mol Genet Genomic Med (2017) 0.75
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer (2015) 0.75
Role of computerized physician order entry systems in facilitating medication errors. JAMA (2005) 26.32
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer (2003) 6.92
Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med (2003) 6.47
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer (2004) 6.41
Genetic structure of the purebred domestic dog. Science (2004) 6.39
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin (2007) 5.67
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Dynamics of mammalian chromosome evolution inferred from multispecies comparative maps. Science (2005) 5.47
Effect of population-based screening on breast cancer mortality. Lancet (2011) 5.06
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg (2015) 4.78
A single IGF1 allele is a major determinant of small size in dogs. Science (2007) 4.68
Genome-wide SNP and haplotype analyses reveal a rich history underlying dog domestication. Nature (2010) 4.64
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med (2013) 4.36
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27
Design of a national distributed health data network. Ann Intern Med (2009) 4.09
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Molecular and evolutionary history of melanism in North American gray wolves. Science (2009) 3.87
Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol (2007) 3.86
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol (2006) 3.79
Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol (2005) 3.65
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res (2006) 3.62
A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet (2007) 3.61
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
A simple genetic architecture underlies morphological variation in dogs. PLoS Biol (2010) 3.46
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer (2004) 3.40
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
An expressed fgf4 retrogene is associated with breed-defining chondrodysplasia in domestic dogs. Science (2009) 3.29
Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005) 3.28
Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer (2003) 3.25
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Assigning African elephant DNA to geographic region of origin: applications to the ivory trade. Proc Natl Acad Sci U S A (2004) 3.17
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev (2003) 3.11
Influence of individual and combined health behaviors on total and cause-specific mortality in men and women: the United Kingdom health and lifestyle survey. Arch Intern Med (2010) 3.08
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage (2003) 3.05
Client-directed interventions to increase community demand for breast, cervical, and colorectal cancer screening a systematic review. Am J Prev Med (2008) 3.05
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol (2003) 3.05
Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (2008) 2.97
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J (2007) 2.89
Physical activity levels among breast cancer survivors. Med Sci Sports Exerc (2004) 2.88
Extensive and breed-specific linkage disequilibrium in Canis familiaris. Genome Res (2004) 2.85
Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol (2008) 2.85
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res (2004) 2.80
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
Long-term exposure to constituents of fine particulate air pollution and mortality: results from the California Teachers Study. Environ Health Perspect (2009) 2.72
Coat variation in the domestic dog is governed by variants in three genes. Science (2009) 2.70
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol (2003) 2.65
Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst (2004) 2.62
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer (2008) 2.56
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
Genetic basis for systems of skeletal quantitative traits: principal component analysis of the canid skeleton. Proc Natl Acad Sci U S A (2002) 2.51